So to get my bearings this is about their imaging service (half cu6 potential) not their treatment service (potentially the far more exciting potential)?
Is that correct?
If so, we still need the “results” of imaging. Ie: the idea is that clarity’s imaging is far superior to not only standard modalities, but even illucix from Telix.
So, was it? If we do not get that information until 260 patients, why is this announcement significant? It’s almost irrelevant as we know they are on an imaging path. Isn’t it of very minor interest they have done their first one? Sure tell us but say No to market sensitive news, not yes.
Ann: First patient imaged in Phase III AMPLIFY trial, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.23 |
Change
0.070(3.24%) |
Mkt cap ! $715.0M | |||
| Open | High | Low | Value | Volume |
| $2.15 | $2.29 | $2.13 | $3.896M | 1.764M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 23897 | $2.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.23 | 262 | 10 |
View Market Depth
| Last trade - 15.54pm 16/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |